These findings suggest that AXL and CAV1 may collaborate to sustain HCC dormancy, potentially contributing to tumour relapse and underscoring their multifaceted roles during HCC progression and therapeutic resistance. The gene discussed is CAV1; the disease is hepatocellular carcinoma.